Compare DKL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKL | NVCR |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.3B |
| IPO Year | N/A | 2015 |
| Metric | DKL | NVCR |
|---|---|---|
| Price | $44.75 | $13.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $45.50 | $28.42 |
| AVG Volume (30 Days) | 50.5K | ★ 1.7M |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | ★ 10.01% | N/A |
| EPS Growth | ★ 9.17 | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $967,420,000.00 | $642,269,000.00 |
| Revenue This Year | $12.80 | $9.75 |
| Revenue Next Year | $11.50 | $5.62 |
| P/E Ratio | $14.47 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $34.59 | $10.70 |
| 52 Week High | $48.00 | $34.13 |
| Indicator | DKL | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 60.37 |
| Support Level | $44.50 | $10.79 |
| Resistance Level | $46.81 | $13.94 |
| Average True Range (ATR) | 1.04 | 0.61 |
| MACD | -0.12 | 0.22 |
| Stochastic Oscillator | 26.69 | 80.48 |
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.